BRIEF published on 09/24/2024 at 23:05, 9 days 23 hours ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 9 days 23 hours ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 10 days ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 14 days 23 hours ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
BRIEF published on 09/19/2024 at 23:10, 14 days 23 hours ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
PRESS RELEASE published on 09/19/2024 at 23:05, 14 days 23 hours ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 month 1 day ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 1 month 1 day ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 month 1 day ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 month 7 days ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 10/04/2024 at 20:45, 2 hours 19 minutes ago ONAR Appoints Sara Wetmore to Lead Corporate Communications and Marketing
Published on 10/04/2024 at 19:00, 4 hours 4 minutes ago Clear Start Tax's Proven Approach to Resolving Client's Tax Debt
Published on 10/04/2024 at 17:00, 6 hours 4 minutes ago Tonight on Bloomberg! New to The Street's Sponsored Lineup Features Exclusive Interviews With Nuburu, PetVivo, the Sustainable Green Team and the Bilingual Book Club. Catch the Latest Insights and Innovations - only on New to The Street!
Published on 10/04/2024 at 15:30, 7 hours 34 minutes ago Vision Marine Technologies Granted Extension for Continued Listing on the Nasdaq Stock Market
Published on 10/04/2024 at 15:09, 7 hours 55 minutes ago Justera Health Announces Debt Settlement Transaction
Published on 10/04/2024 at 18:33, 4 hours 30 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 10/04/2024 at 18:15, 4 hours 48 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 10/04/2024 at 17:20, 5 hours 44 minutes ago The subscription price for exercise of warrants series TO5 has been determined to SEK 0.40
Published on 10/04/2024 at 16:55, 6 hours 9 minutes ago World Green Economy Summit 2024 Hosts a High-Level Ministerial Roundtable
Published on 10/04/2024 at 18:30, 4 hours 34 minutes ago ALTAREIT : DECLARATION MENSUELLE DES OPERATIONS REALISEES PAR LA SOCIETE SUR SES PROPRES TITRES SEPTEMBRE 2024
Published on 10/04/2024 at 18:30, 4 hours 34 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 10/04/2024 at 18:30, 4 hours 34 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 10/04/2024 at 18:30, 4 hours 34 minutes ago ALTAREA : DECLARATION MENSUELLE DES OPERATIONS REALISEES PAR LA SOCIETE SUR SES PROPRES TITRES SEPTEMBRE 2024
Published on 10/04/2024 at 18:27, 4 hours 36 minutes ago Total number of voting rights and shares making up the share capital at September 30, 2024
